LOGO
LOGO

Biofrontera Posts Preliminary Q4 Results; Ameluz Uptake Drives Growth, Trial Results Due In February

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us

Biofrontera Inc. (BFRI) has announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025.The Massachusetts-based speciality dermatology company, focused on photodynamic therapy and topical antibiotics, attributed growth to robust demand for its Ameluz PDT franchise and a December pricing adjustment.Ameluz (aminolevulinic acid hydrochloride gel, 10%) is used in com...

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19